The Role of Sodium-Glucose Cotransporter Inhibitors with AID Systems in Diabetes Treatment: Is Continuous Ketone Monitoring the Solution?

Biester T , Tauschmann M , Chobot A , et al. The automated pancreas: A review of technologies and clinical practice. Diabetes Obes Metab, 2021; 24 (suppl 1):43–57; doi: 10.1111/dom.14576.

Holt RIG , DeVries JH , Hess-Fischl A , et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2021; 44(11):2589–2625; doi: 10.2337/dci21-0043.

Weisman A , Bai J-W , Cardinez M , et al. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: A systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol, 2017; 5(7):501–512; doi: 10.1016/S2213-8587(17)30167-5.

Bekiari E , Kitsios K , Thabit H et al . Artificial pancreas treatment for outpatients with type 1 diabetes: Systematic review and meta-analysis. BMJ 2018;361:k1310; doi: 10.1136/bmj.k1310.

Battelino T , Danne T , Bergenstal RM et al . Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care, 2019; 42(8):1593–1603; doi: 10.2337/dci19-0028.

Kimbell B , Rankin D , Hart RI et al . Parents' experiences of using a hybrid closed-loop system (CamAPS FX) to care for a very young child with type 1 diabetes: Qualitative study. Diabetes Res Clin Pract 2022;187:109877; doi: 10.1016/j.diabres.2022.109877.

Messer LH , Campbell K , Pyle L , et al. Basal-IQ technology in the real world: Satisfaction and reduction of diabetes burden in individuals with type 1 diabetes. Diabet Med 2021;38(6):e14381; doi: 10.1111/dme.14381.

Bisio A , Brown SA , McFadden R , et al. Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents. Pediatr Diabetes, 2021; 22(3):495–502; doi: 10.1111/pedi.13164.

Danne T , Nimri R , Battelino T , et al. International consensus on use of continuous glucose monitoring. Diabetes Care, 2017; 40(12):1631–1640; doi: 10.2337/dc17-1600.PMID:29162583;PMCID:PMC6467165.

Danne T , Biester T , Kordonouri O . Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care. Diabetes Technol Ther, 2018; 20(S2):S269–S277; doi: 10.1089/dia.2018.0081.

Garcia-Tirado J , Farhy L , Nass R et al. Automated insulin delivery with SGLT2i combination therapy in type 1 diabetes. Diabetes Technol Ther, 2022; 24(7):461–470; doi 10.1089/dia.2021.0542

Henry RR , Dandona P , Pettus J et al. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab, 2017; 19(6):814–821; doi: 10.1111/dom.12882.

Garg SK , Henry RR , Banks P et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med, 2017; 377(24):2337–2348; doi: 10.1056/NEJMoa1708337.

Dandona P , Mathieu C , Phillip M et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-week study. Diabetes Care, 2018; 41(12):2552–2559; doi: 10.2337/dc18-1087.

Mathieu C , Rudofsky G , Phillip M , et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial. Diabetes Obes Metab, 2020; 22(9):1516–1526; doi: 10.1111/dom.14060.

Biester T , Kordonouri O , Danne T . Beyond type 2 diabetes: Sodium glucose co-transporter-inhibition in type 1 diabetes. Diabetes Obes Metab, 2019; 21(Suppl 2):53–61; doi: 10.1111/dom.13659.

Haidar A , Yale JF , Lovblom LE , et al. Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial. Diabetes Obes Metab, 2021; 23(6):1272–1281; doi: 10.1111/dom.14335

Biester T , Muller I , von dem Berge T , et al. Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study. Diabetes Obes Metab, 2021; 23(2):599–608; doi: 10.1111/dom.14258.

Danne T , Garg S , Peters AL , et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care, 2019; 42(6):1147–1154; doi: 10.2337/dc18-2316.

Singh S , Rushakoff RJ , Neinstein AB . A case report of diabetic ketoacidosis with combined use of a sodium glucose transporter 2 inhibitor and hybrid closed-loop insulin delivery. J Diabetes Sci Technol, 2019; 13(3):605–606; doi: 10.1177/1932296819838875.

Peters AL , Buschur EO , Buse JB , et al. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care, 2015; 38(9):1687–1693; doi: 10.2337/dc15-0843.

Cherubini V , Grimsmann JM , Åkesson K , et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: Results from 13 countries in three continents. Diabetologia, 2020; 63(8):1530–1541; doi: 10.1007/s00125-020-05152-1.

Seufert J , Lanzinger S , Danne T , et al. DPV initiative. Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis. Diabetes Obes Metab, 2022; 24(4):742–746; doi: 10.1111/dom.14620.

Albanese-O'Neill A , Wu M , Miller KM , et al. Poor adherence to ketone testing in patients with type 1 diabetes. Diabetes Care, 2017; 40(4):e38–e39; doi: 10.2337/dc16-2620.

Patel NS , Van Name MA , Cengiz E , et al. Altered patterns of early metabolic decompensation in type 1 diabetes during treatment with a SGLT2 inhibitor: An insulin pump suspension study. Diabetes Technol Ther, 2017; 19(11):618–622; doi: 10.1089/dia.2017.0267.

Abbott-Announces-Development-of-Novel-Continuous-Glucose-Ketone-Monitoring-System [press release]. Available from: https:/abbott.mediaroom.com/2022-06-03-Abbott-Announces-Development-of-Novel-Continous-Glucose-Ketone-Monitoring-System [Last accessed: March 6, 2022].

Nguyen KT , Xu NY , Zhang JY , et al. Continuous ketone monitoring consensus report 2021. J Diabetes Sci Technol, 2022; 16(3):689–715; doi: 10.1177/19322968211042656.

Alva S , Castorino K , Cho H , et al. Feasibility of continuous ketone monitoring in subcutaneous tissue using a ketone sensor. J Diabetes Sci Technol, 2021; 15(4):768–774; doi: 10.1177/19322968211008185.

Danne T , Ampudia-Blasco FJ , Mathieu C . Diabetes and the WHO model list of essential medicines. Lancet Diabetes Endocrinol, 2022; 10(1):18–19; doi: 10.1016/S2213-8587(21)00322-3.

Czupryniak L , Danne T , Szymańska-Garbacz E , et al. Sodium-glucose co-transporter-2 inhibitors for type 1 diabetes: Not any more?. Diabetes Obes Metab, 2022; 24(4):764–765; doi: 10.1111/dom.14631.

Zinman B , Wanner C , Lachin JM , et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015; 373(22):2117–2128; doi: 10.1056/NEJMoa1504720.

Zannad F , Ferreira JP , Pocock SJ , et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, 2020; 396(10254):819–829; doi: 10.1016/S0140-6736(20)31824-9.

Kosiborod M , Cavender MA , Fu AZ , et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation, 2017; 136(3):249–259; doi: 10.1161/CIRCULATIONAHA.117.029190.

Rawshani A , Sattar N , Franzén S , et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: A nationwide, register-based cohort study. Lancet, 2018; 392(10146):477–486; doi: 10.1016/S0140-6736(18)31506-X.